HC Wainwright Has Weak Outlook for uniQure FY2024 Earnings

uniQure (NASDAQ:QURE) – Analysts at HC Wainwright cut their FY2024 EPS estimates for shares of uniQure in a research report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of ($4.17) per share for the year, down from their prior forecast of ($4.16). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS and FY2028 earnings at $16.97 EPS.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

Several other equities analysts have also recently issued reports on the stock. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Mizuho lifted their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Price Performance

uniQure stock opened at $15.79 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business has a 50 day simple moving average of $13.50 and a 200-day simple moving average of $8.88. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The stock has a market capitalization of $769.60 million, a PE ratio of -3.18 and a beta of 0.41.

Hedge Funds Weigh In On uniQure

Institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. grew its position in shares of uniQure by 336.1% in the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the period. Walleye Capital LLC acquired a new position in uniQure during the third quarter worth approximately $444,000. FMR LLC increased its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Sanders Morris Harris LLC raised its position in shares of uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after buying an additional 34,034 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in uniQure during the third quarter valued at about $7,360,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.74% of the stock is currently owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.